05 May 2006 - Boston Scientific Corporation and Angiotech Pharmaceuticals, Inc. announced that they received a favorable decision from a Dutch court in a patent dispute against Sahajanand Medical Technologies Pvt. Ltd. Boston Scientific and Angiotech alleged that Sahajanand's Infinnium paclitaxel-eluting stent infringed two claims of an Angiotech patent directed to paclitaxel stents. The Court found that the asserted claims were infringed and valid.
The Court granted Boston Scientific and Angiotech an injunction against Sahajanand, prohibiting the company from selling, bringing onto the market and delivering -- as well as importing, offering or keeping in stock for one of these purposes -- the infringing Infinnium paclitaxel stent in the Netherlands. The Court also ordered Sahajanand to pay damages and/or surrender profits resulting from the infringement. The Court's decision can be appealed by Sahajanand.
 |
www.bionity.com/news/e/54472 |
|
 |
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/54472 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |